Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?
- PMID: 17720359
- DOI: 10.1016/j.amjmed.2007.06.005
Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?
Abstract
Risk assessment algorithms, such as that used in the third Adult Treatment Panel (ATP III) of the National Cholesterol Education Program (NCEP) for treating low-density lipoprotein cholesterol, can be used to classify patients' risk for cardiovascular and metabolic problems and to determine the appropriate level of therapeutic intervention. Patients at highest risk should receive the most intensive therapy. The presence of the metabolic syndrome, a clustering of atherogenic risk factors including dyslipidemia, elevated blood pressure, elevated blood glucose, and other problems, confers additional risk for diabetes mellitus and atherosclerotic cardiovascular disease at every level of risk. Pharmacotherapy with lipid-lowering, antiplatelet, antihypertensive, or insulin-sensitizing agents to modify specific risk factors is indicated in patients at higher risk, but lifestyle change (e.g., smoking cessation, weight reduction, increased physical activity, and "heart-healthy" dietary modifications) and blood pressure control can be used across all categories of risk.
Similar articles
-
New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.Curr Probl Cardiol. 2005 May;30(5):241-79. doi: 10.1016/j.cpcardiol.2004.10.001. Curr Probl Cardiol. 2005. PMID: 15829899 Review.
-
Characteristics of US adults with the metabolic syndrome and therapeutic implications.Diabetes Obes Metab. 2004 Sep;6(5):353-62. doi: 10.1111/j.1462-8902.2004.00354.x. Diabetes Obes Metab. 2004. PMID: 15287928
-
Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.Ren Fail. 2009;31(3):221-8. doi: 10.1080/08860220802669883. Ren Fail. 2009. PMID: 19288328
-
Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.Obesity (Silver Spring). 2006 Jun;14 Suppl 3:128S-134S. doi: 10.1038/oby.2006.292. Obesity (Silver Spring). 2006. PMID: 16931494 Review.
-
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.Am J Cardiol. 2008 Dec 22;102(12A):41L-47L. doi: 10.1016/j.amjcard.2008.09.074. Am J Cardiol. 2008. PMID: 19084089 Review.
Cited by
-
Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.Ann Gen Psychiatry. 2011 Sep 19;10:22. doi: 10.1186/1744-859X-10-22. Ann Gen Psychiatry. 2011. PMID: 21929761 Free PMC article.
-
Metabolic syndrome and hepatic resection: improving outcome.HPB (Oxford). 2011 Dec;13(12):846-59. doi: 10.1111/j.1477-2574.2011.00380.x. Epub 2011 Oct 19. HPB (Oxford). 2011. PMID: 22081919 Free PMC article. Review.
-
Genetic variations of HSPA1A, the heat shock protein levels, and risk of atherosclerosis.Cell Stress Chaperones. 2012 Jul;17(4):507-16. doi: 10.1007/s12192-012-0328-4. Epub 2012 Feb 11. Cell Stress Chaperones. 2012. PMID: 22328194 Free PMC article.
-
Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome.Pediatr Gastroenterol Hepatol Nutr. 2020 May;23(3):189-230. doi: 10.5223/pghn.2020.23.3.189. Epub 2020 May 8. Pediatr Gastroenterol Hepatol Nutr. 2020. PMID: 32483543 Free PMC article. Review.
-
Weight control and prevention of metabolic syndrome by green tea.Pharmacol Res. 2011 Aug;64(2):146-54. doi: 10.1016/j.phrs.2010.12.013. Epub 2010 Dec 28. Pharmacol Res. 2011. PMID: 21193040 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical